BRCA1 免疫组化染色作为子宫浆液性癌的预后指标。
BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
机构信息
Department of Obstetrics and Gynaecology, Antrim Area Hospital, Antrim, United Kingdom.
出版信息
Int J Gynecol Cancer. 2013 Jan;23(1):113-8. doi: 10.1097/IGC.0b013e3182798188.
OBJECTIVES
The objective of this study was to investigate the relationship between BRCA1 protein expression, as determined by immunohistochemistry, and clinical outcome in uterine serous carcinoma (USC).
METHODS
A tissue microarray containing duplicate cores of 73 cases of USC was immunohistochemically stained with mouse anti-BRCA1 (Ab-1) mouse monoclonal (MS110) antibody. The cores were scored in a semiquantitative manner evaluating both the distribution and intensity of nuclear staining. BRCA1 protein expression was correlated with progression-free survival.
RESULTS
Seventy-two of 73 cases were assessable, and there was a statistically significant decreased progression-free survival for those cases exhibiting tumor cell nuclei staining of 76% or greater (P = 0.0023).
CONCLUSIONS
Our study illustrates that a low level of BRCA1 protein expression is a favorable prognostic indicator in USC, similar to what is observed in high-grade serous ovarian carcinoma. Further studies should focus on the BRCA1 status of USCs at a molecular level and also investigate whether BRCA1 protein expression is associated with response to chemotherapy in USC.
目的
本研究旨在探讨免疫组织化学检测到的 BRCA1 蛋白表达与子宫浆液性癌（USC）临床结局之间的关系。
方法
使用小鼠抗 BRCA1（Ab-1）单克隆抗体（MS110）对包含 73 例 USC 病例的组织微阵列进行免疫组织化学染色。以半定量方式对核染色的分布和强度进行评分。BRCA1 蛋白表达与无进展生存期相关。
结果
73 例中有 72 例可评估，肿瘤细胞核染色≥76%的病例无进展生存期明显缩短（P=0.0023）。
结论
本研究表明，BRCA1 蛋白低表达是 USC 的有利预后指标，与高级别浆液性卵巢癌相似。进一步的研究应侧重于 USC 的 BRCA1 状态的分子水平，并探讨 BRCA1 蛋白表达是否与 USC 对化疗的反应相关。
Zotero 插件